Analysts Set NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Price Target at $38.25

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) have received an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $38.25.

A number of brokerages have commented on NRXP. D. Boral Capital reiterated a “buy” rating and issued a $34.00 target price on shares of NRx Pharmaceuticals in a report on Tuesday, May 5th. Weiss Ratings restated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a report on Friday, May 8th. Wall Street Zen raised shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, June 14th. HC Wainwright reiterated a “buy” rating and set a $45.00 price objective on shares of NRx Pharmaceuticals in a research note on Monday, April 27th. Finally, Ascendiant Capital Markets increased their target price on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the company a “buy” rating in a research report on Monday, April 27th.

NRx Pharmaceuticals Trading Down 8.8%

Shares of NASDAQ NRXP opened at $3.75 on Tuesday. NRx Pharmaceuticals has a 12-month low of $1.62 and a 12-month high of $5.05. The stock’s fifty day simple moving average is $3.96 and its two-hundred day simple moving average is $2.85. The stock has a market capitalization of $135.86 million, a PE ratio of -3.44 and a beta of 2.19.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.01. The company had revenue of $1.07 million during the quarter, compared to the consensus estimate of $19.43 million. On average, equities analysts predict that NRx Pharmaceuticals will post -0.3 earnings per share for the current fiscal year.

Institutional Trading of NRx Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in NRXP. Anson Funds Management LP boosted its position in shares of NRx Pharmaceuticals by 50.3% in the 4th quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock worth $8,249,000 after purchasing an additional 1,018,853 shares in the last quarter. Commonwealth Equity Services LLC acquired a new position in NRx Pharmaceuticals during the 4th quarter valued at about $994,000. Bleakley Financial Group LLC purchased a new stake in shares of NRx Pharmaceuticals during the fourth quarter worth about $318,000. AdvisorShares Investments LLC grew its stake in shares of NRx Pharmaceuticals by 28.2% during the first quarter. AdvisorShares Investments LLC now owns 420,467 shares of the company’s stock worth $896,000 after acquiring an additional 92,463 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of NRx Pharmaceuticals by 18.3% in the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after purchasing an additional 82,781 shares during the last quarter. Hedge funds and other institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.